Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.
Related to this article
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Advertisement
Advertisement
Trending on OncLive
1
Rusfertide Maintains Clinical Response and Hematocrit Control Across Risk Groups in Polycythemia Vera
2
Dibotatug Is Safe and Yields Durable Responses in Large Granular Lymphocytic Leukemia
3
Dr Bose on the Potential Role of Selinexor Plus Ruxolitinib in Myelofibrosis
4
Dr Gangat on Efficacy Data for Selcodebart in Myelofibrosis-Associated Anemia
5